Back to Search Start Over

Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast

Authors :
Marc B. I. Lobbes
Flora E. van Leeuwen
Hinne A. Rakhorst
René R. W. J. van der Hulst
Mintsje de Boer
Lucy I. H. Overbeek
Michael Hauptmann
Caroline A H Klazen
Daphne de Jong
Arthur Sernee
Nathalie J. Hijmering
Jan de Boer
Promovendi ODB
Plastische Chirurgie (PLC)
RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy
Beeldvorming
MUMC+: DA BV Medisch Specialisten Radiologie (9)
RS: NUTRIM - R2 - Liver and digestive health
MUMC+: MA Plastische Chirurgie (3)
Epidemiology and Data Science
APH - Quality of Care
CCA - Cancer Treatment and quality of life
Pathology
VU University medical center
AGEM - Re-generation and cancer of the digestive system
Amsterdam Neuroscience - Cellular & Molecular Mechanisms
Source :
JAMA Oncology, 4(3), 335-341. American Medical Association, de Boer, M, van Leeuwen, F E, Hauptmann, M, Overbeek, L I H, de Boer, J P, Hijmering, N J, Sernee, A, Klazen, C A H, Lobbes, M B I, van der Hulst, R R W J, Rakhorst, H A & de Jong, D 2018, ' Breast implants and the risk of anaplastic large-cell lymphoma in the breast ', JAMA Oncology, vol. 4, no. 3, pp. 335-341 . https://doi.org/10.1001/jamaoncol.2017.4510
Publication Year :
2018

Abstract

IMPORTANCE Breast implants are among the most commonly used medical devices. Since 2008, the number of women with breast implants diagnosed with anaplastic large-cell lymphoma in the breast (breast-ALCL) has increased, and several reports have suggested an association between breast implants and risk of breast-ALCL. However, relative and absolute risks of breast-ALCL in women with implants are still unknown, precluding evidence-based counseling about implants. OBJECTIVE To determine relative and absolute risks of breast-ALCL in women with breast implants. DESIGN, SETTING, AND PARTICIPANTS Through the population-based nationwide Dutch pathology registry we identified all patients diagnosed with primary non-Hodgkin lymphoma in the breast between 1990 and 2016 and retrieved clinical data, including breast implant status, from the treating physicians. We estimated the odds ratio (OR) of ALCL associated with breast implants in a case-control design, comparing implant prevalence between women with breast-ALCL and women with other types of breast lymphoma. Cumulative risk of breast-ALCL was derived from the age-specific prevalence of breast implants in Dutch women, estimated from an examination of 3000 chest x-rays and time trends from implant sales. MAIN OUTCOMES AND MEASURES Relative and absolute risks of breast-ALCL in women with breast implants. RESULTS Among 43 patients with breast-ALCL (median age, 59 years), 32 had ipsilateral breast implants, compared with 1 among 146 women with other primary breast lymphomas (OR, 421.8; 95% CI, 52.6-3385.2). Implants among breast-ALCL cases were more often macrotextured (23 macrotextured of 28 total implants of known type, 82%) than expected (49 193 sold macrotextured implants of total sold 109 449 between 2010 and 2015, 45%) based on sales data (P < .001). The estimated prevalence of breast implants in women aged 20 to 70 years was 3.3%. Cumulative risks of breast-ALCL in women with implants were 29 per million at 50 years and 82 per million at 70 years. The number of women with implants needed to cause 1 breast-ALCL case before age 75 years was 6920. CONCLUSIONS AND RELEVANCE Breast implants are associated with increased risk of breast-ALCL, but the absolute risk remains small. Our results emphasize the need for increased awareness among the public, medical professionals, and regulatory bodies, promotion of alternative cosmetic procedures, and alertness to signs and symptoms of breast-ALCL in women with implants.

Details

ISSN :
23742445 and 23742437
Volume :
4
Issue :
3
Database :
OpenAIRE
Journal :
JAMA oncology
Accession number :
edsair.doi.dedup.....61434a6b279bb55a2df879a7f24d9eb6
Full Text :
https://doi.org/10.1001/jamaoncol.2017.4510